OTC pharma is influenced by changes in consumer spending - but significant commercial opportunities for OTC switching will drive market expansion worldwide. This new report explains general economic trends worldwide will affect the over-the-counter (OTC) pharma market from 2009 onwards, with both market restraints and opportunities present. The Global OTC Pharmaceutical Market report notes that Rx-to-OTC switching and the continuing importance of emerging pharma markets will drive OTC sales growth from 2009 onwards. The report forecasts reveal that the OTC pharma market will grow significantly next decade and explains where future OTC switching will occur, providing you with the information that you need to understand the current OTC market and its future prospects. The potential of this market remains significant, despite general economic uncertainty.

The Global OTC Pharmaceutical Market 2009-2024 examines all the major categories of OTC pharmaceuticals, including:

• Analgesics – for internal and external uses
• Cough, cold and allergy preparations
• Dermatology - including antifungal agents and hair-loss treatments
• Gastrointestinal drugs - including those for acid-related disorders, laxatives and anti-diarrhoea preparations
• Anti-obesity treatments
• Smoking cessation aids
• Others – including contraceptives, statins and erectile dysfunction areas.

Demographic trends, lifestyles changes and clinical advances are transforming medicine and creating opportunities for therapeutic areas and drug types in OTC pharma. Consumers are increasingly willing to self-medicate, for convenience and cost savings in particular. New regulations are changing OTC retail channels and sales processes, including the range of products on offer. Importantly, governments and healthcare providers are promoting self-medication, viewing the process as a tool to help contain healthcare expenditure. Therefore the OTC pharma market holds high potential for continued growth in both mature and emerging geographical markets.

Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Competing with private labels, gaining regulatory approval for further OTC switches and harnessing Web 2.0 in advertising are all challenges that are assessed in this report, along with other aspects of the market.

Comprehensive analysis of the OTC market area

The Global OTC Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 100 tables and figures included. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to aid your work.

Why you should buy The Global OTC Pharmaceutical Market 2009-2024

Benefits from purchasing this report include:

• Your receiving a comprehensive appraisal of the OTC pharmaceutical market in 2008, including sales revenues and market shares for OTC categories, the top 10 companies and the leading OTC brands
• Your receiving sales forecasts and discussions covering the period 2009 to 2024, including the global OTC market, leading OTC brand forecasts, top OTC manufacturer forecasts and therapeutic category forecasts
• Your viewing sales forecasts for leading national OTC markets worldwide
• Your receiving coverage of OTC switching from 2009 onwards, with important developments that you cannot ignore
• Your viewing strengths, weaknesses, opportunities and threats facing the industry, with an emphasis on commercial drivers and restraints.

TABLE OF CONTENTS

1 Executive Summary

2 Introduction to OTC Pharmaceuticals

2.1 OTC Pharmaceuticals
2.2 Key Features of OTC Pharmaceuticals
2.3 OTC Switching
2.4 Manufacture and Distribution of OTC Pharmaceuticals
2.5 Regulation of OTC Pharmaceuticals
2.5.1 United States
2.5.2 Japan
2.5.3 European Union
2.5.4 Other Countries
2.6 Major OTC Pharmaceutical Therapeutic Categories
2.7 Analgesics
2.7.1 Internal Analgesics
2.7.2 External Analgesics
2.8 Cough, Cold and Allergy Products
2.8.1 Cough and Cold Remedies
2.8.2 Anti-Allergy OTC Products
2.9 Dermatological Products
2.9.1 Minor Cuts and Wounds
2.9.2 Acne
2.9.3 Rashes, Itchy Skin, Dermatitis and Eczema
2.9.4 Cold Sores
2.9.5 Warts
2.9.6 Fungal Skin Infections
2.9.7 Haemorrhoids
2.9.8 Other Dermatological Products
2.10 Gastrointestinal Products
2.10.1 Indigestion and Heartburn
2.10.2 Anti-Diarrhoea OTC Pharmaceuticals
2.10.3 Laxatives
2.10.4 Anti-Emetic OTC Pharmaceuticals
2.10.5 Anti-Obesity OTC Pharmaceuticals
2.11 Smoking Cessation Aids
2.12 Other OTC Pharmaceuticals
2.13 Vitamins, Minerals and Supplements

3 The Global OTC Pharmaceutical Market

3.1 Global OTC Pharmaceutical Market
3.1.1 The Global OTC Market in 2008
3.1.2 Economic Downturn and OTC Switching: Global OTC Pharmaceutical Market Forecast, 2009-2024
3.1.3 World OTC Market to Increase 75% from 2008 Value by 2024
3.2 OTC Pharmaceutical Categories
3.2.1 OTC Category Revenues and Market Share, 2008
3.2.2 OTC Category Sales Forecasts, 2009-2024
3.3 Leading OTC Pharmaceutical Brands
3.4 Leading OTC Pharmaceutical Manufacturers
3.5 Johnson & Johnson
3.5.1 Johnson & Johnson’s OTC Pharmaceuticals and Nutritionals Franchise
3.5.2 The Global OTC Leader: Johnson & Johnson’s 2008 OTC Sales Revenues and Market Shares
3.5.3 Johnson & Johnson OTC Pharmaceutical Forecast, 2009-2014
3.5.4 Tylenol: The Only Billion Dollar OTC Brand
3.5.5 Tylenol Sales Forecast, 2009-2024
3.5.6 Johnson & Johnson’s Nicorette Nicotine Replacement Therapy
3.5.7 Nicorette Sales Forecast, 2009-2024
3.5.8 Zyrtec OTC/Reactine: Johnson’s & Johnson’s Fastest-Growing Brand of 2008
3.5.9 Other Leading Johnson & Johnson OTC Pharmaceuticals
3.6 GlaxoSmithKline
3.6.1 GSK Consumer Healthcare
3.6.2 GSK is Second-Largest Global OTC Pharmaceutical Company: 2008 OTC Sales and Market Shares
3.6.3 GSK OTC Pharmaceutical Forecast, 2009-2014
3.6.4 Panadol: GSK’s International Analgesic
3.6.5 Panadol Sales Forecast, 2009-2024
3.6.6 Nicabate/NicoDerm/Nicorette/NiQuitin Smoking Cessation Brands
3.6.7 Nicabate/NicoDerm/Nicorette/NiQuitin Sales Forecast, 2009-2024
3.6.8 alli: Pioneer OTC-Switch Diet Aid
3.6.9 alli Sales Forecast, 2009-2024
3.6.10 Other GSK Products with Revenues over $100m
3.7 Bayer
3.7.1 Bayer Consumer Care
3.7.2 Bayer’s OTC Pharmaceuticals: 2008 Sales and Market Shares
3.7.3 Bayer OTC Pharmaceutical Forecast, 2009-2014
3.7.4 Bayer Aspirin
3.7.5 Bayer Aspirin Sales Forecast, 2009-2024
3.7.6 Other Bayer OTC Pharmaceuticals
3.8 Novartis
3.8.1 Novartis OTC Pharmaceuticals
3.8.2 Sales and Market Share of Leading Novartis OTC Products in 2008
3.8.3 Novartis OTC Pharmaceutical Forecast, 2009-2014
3.8.4 Voltaren
3.8.5 Novartis’ Nicotine Replacement Business
3.8.6 Otriven, Theraflu, Excedrin and Lamisil: Other Leading Novartis OTC Brands
3.9 Proctor & Gamble
3.9.1 Proctor & Gamble OTC Pharmaceuticals
3.9.2 Prilosec OTC
3.9.3 Prilosec OTC Will Face Competition from Generics and Newer OTC Heartburn Drugs
3.9.4 Vicks
3.9.5 Vicks Market Forecast, 2009-2024
3.10 Wyeth/Pfizer
3.10.1 Wyeth Consumer Healthcare
3.10.2 Wyeth OTC Pharmaceuticals: 2008 Sales and Market Shares
3.10.3 Advil
3.10.4 Advil Market Forecast, 2009-2024
3.11 Sanofi-Aventis
3.11.1 Sanofi-Aventis OTC Division
3.11.2 Sales and Market Share of Sanofi-Aventis OTC Pharmaceuticals
3.12 Reckitt Benckiser
3.12.1 Reckitt Benckiser OTC Pharmaceuticals
3.12.2 Sales and Market Share of Reckitt Benckiser OTC Pharmaceuticals
3.13 Boehringer Ingelheim
3.13.1 Boehringer Ingelheim Consumer Health Care
3.13.2 Sales and Market Share of Leading Boehringer Ingelheim OTC Pharmaceuticals
3.13.3 The Dulcolax Franchise
3.13.4 Mucosolvan/Lasolvan and other Leading OTC Products
3.14 Perrigo
3.14.1 Perrigo Consumer Healthcare
3.14.2 Perrigo OTC Pharmaceuticals

4 OTC Switching

4.1 Motivations for OTC Switching
4.2 Recent OTC-Switching Activity
4.3 The Future Prospects for OTC Switching
4.4 Interview with Joshua P. Cohen, Ph.D., Senior Research Fellow at the Tufts Center for the Study of Drug Development
4.4.1 Prospects for OTC Statins in the US
4.4.2 Future OTC Switching Categories
4.4.3 Prospects for Behind-the Counter in the US
4.4.4 OTC Safety Issues
4.5 Gastrointestinal OTC Switching
4.5.1 H2-Blockers
4.5.2 PPIs Focus of Gastrointestinal OTC Switching
4.5.3 Omeprazole
4.5.4 Lansoprazole
4.5.5 Pantoprazole
4.5.6 Esomeprazole
4.5.7 Rabeprazole
4.5.8 Anti-Obesity OTC Switches
4.6 Cough, Cold and Allergy OTC Switching
4.6.1 First Generation Antihistamines
4.6.2 Second Generation Antihistamines
4.6.3 Third Generation Antihistamine
4.6.4 Fluticasone Propionate
4.7 Analgesic OTC Switching
4.7.1 Triptans
4.7.2 What are the Prospects for OTC Switching of Triptans in the US?
4.7.3 Arthritis Pain
4.8 Dermatological Drugs
4.9 Other OTC-Switching Categories
4.9.1 Oral Contraceptives
4.9.2 Cholesterol-Lowering Drugs
4.9.2.1 OTC Statins
4.9.2.2 The UK’s Zocor Heart-Pro
4.9.2.3 The Road to OTC Statins in the US
4.9.2.4 What are the Worldwide Prospects for Statin OTC Switching?
4.9.3 Erectile Dysfunction Drugs
4.10 OTC Switching: A Continuing Trend during 2009-2024

5 Issues Affecting the OTC Pharmaceutical Industry

5.1 SWOT Analysis of the OTC Pharmaceutical Industry
5.2 OTC Switching
5.3 Brand Identity and Private Labels
5.4 Developments in OTC Retail Channels
5.5 Will OTC Move Behind-the-Counter?
5.6 Web 2.0 Advertising Opportunities
5.7 Changing World Demographics
5.7.1 Population Increase and ‘Greying’ of the World Population
5.7.2 Emerging-Market Economies
5.8 The Worldwide Downturn in Consumer Spending, 2009-2010
5.9 Safety Concerns, Misuse and Abuse of OTC Pharmaceuticals
5.9.1 Safety Concerns
5.9.2 OTC Drug Misuse
5.9.3 OTC Drug Abuse
5.9.4 Impact on the OTC Industry

6 Leading OTC Pharmaceutical Country Markets

6.1 Leading OTC Country Markets in 2008
6.2 Leading OTC Country Markets Forecasts, 2009-2024
6.3 The US OTC Market
6.4 The Japanese OTC Market
6.5 European OTC Markets
6.6 Emerging OTC Markets

7 Conclusions

7.1 The Global OTC Market in 2008
7.1.1 Leading OTC Categories
7.1.2 Leading OTC Brands
7.1.3 Leading OTC Pharmaceutical Manufacturers
7.1.4 Leading OTC Country Markets
7.2 Global OTC Pharmaceutical Market Forecast, 2009-2024
7.2.1 OTC Growth Drivers
7.2.2 OTC Switching Activity
7.2.3 Emerging OTC Markets
7.3 Future OTC Market Dynamics

List of Tables

Table 2.1 OTC Internal Analgesic Active Ingredients
Table 2.2 OTC External Analgesic Active Ingredients
Table 2.3 Cough, Cold and Allergy OTC Pharmaceutical Active Ingredients
Table 2.4 Antifungal OTC Pharmaceutical Active Ingredients
Table 2.5 Indigestion and Heartburn OTC Pharmaceutical Active Ingredients
Table 2.6 Anti-Diarrhoea OTC Pharmaceutical Active Ingredients
Table 2.7 OTC Laxative Active Ingredients
Table 2.8 Nicotine Replacement Therapy OTC Formulations
Table 3.1 OTC and Prescription-Only Pharmaceutical Markets, 2008
Table 3.2 World OTC Pharmaceuticals Sales Forecast, 2009-2014
Table 3.3 World OTC Pharmaceuticals Sales Forecast, 2015-2024
Table 3.4 OTC Category Revenues and Market Share, 2008
Table 3.5 OTC Category Sales Forecast, 2009-2024
Table 3.6 Top Eight OTC Brands, 2008
Table 3.7 Top Ten OTC Pharmaceutical Manufacturers, 2008
Table 3.8 Johnson & Johnson OTC Brands: 2008 Sales Revenues and Market Share
Table 3.9 Johnson & Johnson Total OTC Pharmaceuticals Sales Forecast, 2009-2014
Table 3.10 Tylenol Products, 2009
Table 3.11 Tylenol Sales Forecast, 2009-2014
Table 3.12 Tylenol Sales Forecast, 2015-2024
Table 3.13 Nicorette Formulations (Johnson & Johnson), 2009
Table 3.14 Nicorette (Johnson & Johnson) Sales Forecast, 2009-2014
Table 3.15 Nicorette (Johnson & Johnson) Sales Forecast, 2015-2024
Table 3.16 GSK OTC Brands: 2008 Sales Revenues and Market Share
Table 3.17 GSK Total OTC Pharmaceuticals Forecast, 2009-2014
Table 3.18 Panadol Formulations, 2009
Table 3.19 Panadol Sales Forecast, 2009-2014
Table 3.20 Panadol Sales Forecast, 2015-2024
Table 3.21 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK), 2009
Table 3.22 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2009-2014
Table 3.23 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2015-2024
Table 3.24 alli Sales Forecast, 2009-2014
Table 3.25 alli Sales Forecast, 2015-2024
Table 3.26 Bayer OTC Brands: 2008 Sales Revenues and Market Share
Table 3.27 Bayer Total OTC Pharmaceuticals Forecast, 2009-2014
Table 3.28 Bayer Aspirin Formulations, 2009
Table 3.29 Bayer Aspirin Sales Forecast, 2009-2014
Table 3.30 Bayer Aspirin Sales Forecast, 2015-2024
Table 3.31 Novartis OTC Brands: 2008 Sales Revenues and Market Share
Table 3.32 Novartis Total OTC Pharmaceuticals Forecast, 2009-2014
Table 3.33 Novartis OTC Nicotine Replacement Therapy Products, 2009
Table 3.34 Proctor & Gamble OTC Brands: 2008 Sales Revenues and Market Share
Table 3.35 Prilosec OTC Sales Forecast, 2009-2014
Table 3.36 Prilosec OTC Sales Forecast, 2015-2024
Table 3.37 Vicks US Formulations, 2009
Table 3.38 Vicks Sales Forecast, 2009-2014
Table 3.39 Vicks Sales Forecast, 2015-2024
Table 3.40 Wyeth OTC Brands: 2008 Sales Revenues and Market Share
Table 3.41 Advil North American Formulations, 2009
Table 3.42 Advil Sales Forecast, 2009-2014
Table 3.43 Advil Sales Forecast, 2015-2024
Table 3.44 Sanofi-Aventis OTC Brands: 2008 Sales Revenues and Market Share
Table 3.45 Reckitt Benckiser OTC Brands: 2008 Sales Revenues and Market Share
Table 3.46 Boehringer Ingelheim OTC Brands: 2008 Sales Revenues and Market Share
Table 4.1 Recent and Future Gastrointestinal OTC Switches
Table 4.2 Recent and Future Cough, Cold & Allergy OTC Switches
Table 4.3 Recent and Future Analgesic OTC Switches
Table 4.4 Recent and Future Dermatological OTC Switches
Table 4.5 Other Possible Future OTC Switches
Table 5.1 SWOT Analysis of the OTC Pharmaceutical Sector, 2009
Table 5.2 World Population Forecast, 2008-2024
Table 5.3 Population Forecasts in Leading OTC Markets, 2008 & 2024
Table 5.4 GDP Forecast for Leading OTC Markets, 2008-2024
Table 6.1 OTC Revenues in Leading OTC Country Markets, 2008
Table 6.2 Leading OTC Country Markets Forecasts, 2009-2024

List of Figures

Figure 2.1 The OTC Pharmaceutical Supply Chain
Figure 3.1 OTC and Prescription-Only Pharmaceutical Markets, 2008
Figure 3.2 World OTC Pharmaceuticals Sales Forecast, 2009-2024
Figure 3.3 OTC Therapies (inc. Vitamins and Minerals) Revenues and Market Shares, 2008
Figure 3.4 OTC Category Revenues and Market Share, 2008
Figure 3.5 OTC Category Sales Forecast, 2009-2024
Figure 3.6 OTC Category Market Share Forecast, 2009-2024
Figure 3.7 Top Ten OTC Pharmaceutical Manufacturers, 2008
Figure 3.8 Top Ten OTC Manufacturers’ Market Shares, 2008
Figure 3.9 Johnson & Johnson OTC Brands: 2008 Market Share
Figure 3.10 Johnson & Johnson Total OTC Pharmaceuticals Sales Forecast, 2009-2014
Figure 3.11 Tylenol Sales Forecast, 2009-2024
Figure 3.12 Nicorette (Johnson & Johnson) Sales Forecast, 2009-2024
Figure 3.13 GSK OTC Brands: 2008 Market Share
Figure 3.14 GSK Total OTC Pharmaceuticals Sales Forecast, 2009-2014
Figure 3.15 Panadol Sales Forecast, 2009-2024
Figure 3.16 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2009-2024
Figure 3.17 alli Sales Forecast, 2009-2024
Figure 3.18 Bayer OTC Brands: 2008 Market Share
Figure 3.19 Bayer Total OTC Pharmaceuticals Sales Forecast, 2009-2014
Figure 3.20 Bayer Aspirin Sales Forecast, 2009-2024
Figure 3.21 Novartis OTC Brands: 2008 Market Share
Figure 3.22 Novartis Total OTC Pharmaceuticals Sales Forecast, 2009-2014
Figure 3.23 Proctor & Gamble OTC Brands: 2008 Market Share
Figure 3.24 Prilosec OTC Sales Forecast, 2009-2024
Figure 3.25 Vicks Sales Forecast, 2009-2024
Figure 3.26 Wyeth OTC Brands: 2008 Market Share
Figure 3.27 Advil Sales Forecast, 2009-2024
Figure 3.28 Sanofi-Aventis OTC Brands: 2008 Market Share
Figure 3.29 Reckitt Benckiser OTC Brands: 2008 Market Share
Figure 3.30 Boehringer Ingelheim OTC Brands: 2008 Market Share
Figure 5.1 World Population Forecast, 2008-2024
Figure 5.2 Forecasted World Population Aged 65 or Over, 2008-2024
Figure 5.3 Population Forecasts in Leading OTC Markets, 2008 & 2024
Figure 5.4 GDP Forecast for Leading OTC Markets, 2008-2024
Figure 6.1 Market Share of Leading OTC Country Markets, 2008
Figure 6.2 Forecast Market Share of Leading OTC Country Markets, 2014
Figure 6.3 Forecast Market Share of Leading OTC Country Markets, 2019
Figure 6.4 Forecast Market Share of Leading OTC Country Markets, 2024
Figure 7.1 World OTC Pharmaceuticals Sales Forecast, 2009-2024